What is the relationship between exacerbations and progression of chronic lung diseases?

How does fetal programming affect adult cardiovascular risk?

Is FVC a valid surrogate for mortality in patients with idiopathic pulmonary disease?

What is the impact of total body ischemia and reperfusion on coagulation, inflammation, and endothelial function?

Researchers at academic institutions, research foundations, and industry are poorly managing clinical data about patients they treat and enroll in clinical trials. A better coordinated patient registry effort related to heart, lung, and blood disease patients would yield long term benefits for clinical research and clinical care improvement.

Well-conducted international epidemiological studies with huge contrast of disease outcome and risk factor exposure will provide clues to disease prevention that cannot be obtained by studies solely within the US.

We know that vasopressin layered on to norepinephrine treatment for septic shock tends to produce better outcomes (VASST trial, Russell et al) than norepinephrine alone. We still need to know if norepinephrine should be first line or if vasopressin should be first line (and perhaps monotherapy) for septic shock.

Heart attacks and strokes cause substantial morbidity and mortality, while implementation of cholesterol and other CV prevention guidelines remain low. Proposed NCQA on-statin in the last year among those with DM was 46% in national field testing, and about 75% in Kaiser Permanente (KP). KP has had some success overcoming barriers to statin, aspirin, and blood pressure medicine adherence. If the nation as a whole is ...more »

What are the efficacy and safety of prophylactic platelet transfusions used to prevent bleeding before common invasive procedures?

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan:

Will integration of behavior science in clinical research improve effectiveness of interventions for asthma associated with behavioral risk factors? 

What are the unique bio-informatics time-series signatures that identify health, disease, response to therappy and can predict impending deterioraiton and select correct therapes base don individual patient performance characteristics.

Can we manipulate the microbiome to modify disease?